Literature DB >> 8560763

Subgroup B adenovirus type 35 early region 3 mRNAs differ from those of the subgroup C adenoviruses.

C F Basler1, M S Horwitz.   

Abstract

Adenovirus type 35 (Ad35) is a member of Ad subgroup B, DNA homology cluster B2. The B2 Ads are unique in that they are isolated most frequently from immunosuppressed individuals such as AIDS patients and bone marrow transplant recipients and in that they have a tropism for the urinary tract. One region of the Ad genome which may influence serotype specific pathology is early region 3 (E3). E3 of subgroup C Ad2 and Ad5 has been shown to encode proteins which counteract the immune response to Ad infection. While a great deal is known about gene expression of the subgroup C Ad E3s, little is known about the E3 gene expression from the subgroup B Ads. Although some E3 open reading frames (ORFs) are shared between subgroups B and C, there are additional ORFs that appear in subgroup B. This paper demonstrates the results of an analysis of gene expression from the Ad35 E3 and describes differences in splicing and polyadenylation between the Ad35 and Ad2 E3s. RT-PCR, cDNA sequencing, RNase protection, 3'RACE, and Northern blotting techniques were utilized to identify, quantify, and determine the structure of six Ad35 E3 mRNAs predicted to encode at least seven proteins. A common intron that is removed during splicing of the subgroup C E3 mRNAs is not removed from Ad35 E3 mRNAs, and only one E3 polyadenylation signal is present in the Ad35 E3 while two polyadenylation signals are used in the formation only one E3 polyadenylation signal is present in the Ad35 E3 while two polyadenylation signals are used in the formation of subgroup C E3 mRNAs. The quantity of individual mRNAs encoding homologous proteins for Ad35 and Ad2 also differ substantially, presumably because of the absence in Ad35 of cis-acting signals which have been shown to be important for regulation of Ad2 E3 pre-mRNA processing. Such information should contribute to an understanding of the role the E3 plays in determining subgroup B Ad pathogenesis in general and Ad35 pathogenesis in particular.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8560763     DOI: 10.1006/viro.1996.0019

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Authors:  Ronald Vogels; David Zuijdgeest; Richard van Rijnsoever; Eric Hartkoorn; Irma Damen; Marie-Pierre de Béthune; Stefan Kostense; Germaine Penders; Niels Helmus; Wouter Koudstaal; Marco Cecchini; Antoinette Wetterwald; Mieke Sprangers; Angelique Lemckert; Olga Ophorst; Björn Koel; Michelle van Meerendonk; Paul Quax; Laura Panitti; Jos Grimbergen; Abraham Bout; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

2.  Characterization of E3/49K, a novel, highly glycosylated E3 protein of the epidemic keratoconjunctivitis-causing adenovirus type 19a.

Authors:  Mark Windheim; Hans-Gerhard Burgert
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Replication-defective vector based on a chimpanzee adenovirus.

Authors:  S F Farina; G P Gao; Z Q Xiang; J J Rux; R M Burnett; M R Alvira; J Marsh; H C Ertl; J M Wilson
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Characterization of human adenovirus 35 and derivation of complex vectors.

Authors:  Duncan McVey; Mohammed Zuber; Damodar Ettyreddy; Christopher D Reiter; Douglas E Brough; Gary J Nabel; C Richter King; Jason G D Gall
Journal:  Virol J       Date:  2010-10-19       Impact factor: 4.099

5.  Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line.

Authors:  Kenneth K W To; Zhirong Zhan; Thomas Litman; Susan E Bates
Journal:  Mol Cell Biol       Date:  2008-06-23       Impact factor: 4.272

6.  Co-infections of adenovirus species in previously vaccinated patients.

Authors:  Gary J Vora; Baochuan Lin; Kevin Gratwick; Carolyn Meador; Christian Hansen; Clark Tibbetts; David A Stenger; Marina Irvine; Donald Seto; Anjan Purkayastha; Nikki E Freed; Marylou G Gibson; Kevin Russell; David Metzgar
Journal:  Emerg Infect Dis       Date:  2006-06       Impact factor: 6.883

7.  Respiratory disease caused by a species B2 adenovirus in a military camp in Turkey.

Authors:  Barbara Chmielewicz; Justus Benzler; Georg Pauli; Gérard Krause; Frank Bergmann; Brunhilde Schweiger
Journal:  J Med Virol       Date:  2005-10       Impact factor: 2.327

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.